Tailoring Treatment Intensity in HNSCC: The Expanding Role of Cancer Immunotherapy - Live

March 3, 2026

Webinar Information

Webinar Description

Immunotherapy has become integrated into therapy for many solid tumors. As this new modality has evolved through recurrent/metastatic and recently into the locally advanced setting, new insights and dangers have been encountered, providing insights into complex interactions of conventional modalities with immunotherapeutic modulation of the tumor microenvironment and clinical benefit for patients. The roles of treatment intensification and de-intensification using immunotherapy will be discussed.

Learning Objectives

  • Understand the current status of approved immunotherapeutic agents in HNSCC
  • Recognize the impact of immunotherapy on the tumor microenvironment in treated tumors including the interaction with conventional oncologic therapies
  • Learn the potential roles of treatment intensification and de-intensification using immunotherapy in locally advanced HNSCC

 

Flyers

Please feel free to share the flyer and/or this webpage.

Using the Learning Portal

Poll Everywhere Link

Please give poll responses via web at:

 

Webinar Registration


Access Zoom

Attending the Webinar

  • Attend online using the link above.
  • Attend in person at North Carolina Basnight Cancer Hospital, Sanofi Aventis Conference Room 1.

Instructions

See our instructions for more information on registering attendance and receiving credit.

Contact us with any questions at [email protected] or (919) 445–1000.

 

Course summary
Available credit: 
  • 1.00 ABIM Medical Knowledge
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
01/16/2026
Course expires: 
03/10/2026
Event starts: 
03/03/2026 - 4:00pm EST
Event ends: 
03/03/2026 - 5:00pm EST
Add to calendar: 
Cancer Grand Rounds Logo 

The Lineberger Cancer Center Grand Rounds are educational activities regarding cancer. We cover the most relevant oncology topics.

These webinars provide FREE continuing education credit.

UNC Lineberger Cancer Grand Rounds are presented as a hybrid event with in-person and online viewing options. 

Image of peopleORImage of webinar icon
In-person at:
Conference Room 1 at the N.C. Basnight Cancer Hospital		 


Online via Zoom:
Link will be provided in confirmation email

 

Photo of Robert L. Ferris, MD, PhD, FACS 

Robert L. Ferris, MD, PhD

Executive Director

Lineberger Comprehensive Cancer Center and UNC Health
UNC-Chapel Hill

Disclosures

Activity Planners
This activity has been planned and implemented under the sole supervision of the Course Directors, Jared Weiss, MD; Deborah Marie Stephens, DO; and Kaitlin Morrison, PhD, of the UNC School of Medicine in association with the UNC Office of Continuing Professional Development (CPD). Dr. Weiss is a stockholder in Vesselon, Nuvalent, En Fuego Therapeutics, Vertex, Merus, Revmed; receives consulting fees from AZ, EMD Serono, Nanobiotix, PDS, Amgen, Pharmacosmos, GSK; and receives research grants from Pharmacosmos, Loxo, PDS, Genmab, Iovance, Nurix, TSCAN, Janus, BMS, Summit. These financial relationships have been mitigated. Dr. Stephens has served on advisory boards for Abbvie, AstraZeneca, BeOne, BMS, Genentech, Pfizer, Pharmacyclics, J&J. These were one time consulting efforts, but she is asked periodically to serve on additional boards. She is a consultant for Abbvie and this is an ongoing relationship. She has also received research grants research grants to Lineberger Comprehensive Cancer Center from BeOne, which are ongoing. Dr. Morrison has no relevant financial relationships with ineligible companies as defined by the ACCME. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. The planning committee members and their relevant financial relationships with ineligible companies as defined by the ACCME can be found at https://learn.unclcn.org/content/lineberger-cancer-center-grand-rounds-planning-committee.

Speaker
The presenter held equity in Novasenta; did consulting work for Bicara Therapeutics; BMS; Bobcat Bio; Coherus BioSciences, Inc; CorriRX Therapeutics; CureVac; FortVita Biologics; Johnson & Johnson; Merck; Merus N.V.; MeiraGTx; Nanobiotix, Novasenta, Novotech; Pfizer; and Regeneron; and received research support from Astra-Zeneca/MedImmune, Merck, and Merus N.V. These financial relationships have been mitigated by UNC CPD.

 

Accreditation Statements

1.00 ABIM MOC Part 2 Credit
CME MOC ABIM badge
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Part 2 credit.

1.00 AMA PRA Category 1 Credit™
The School of Medicine of The University of North Carolina at Chapel Hill designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The School of Medicine of the University of North Carolina at Chapel Hill designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Notice

Attendees are required to view a minimum of 53 minutes of the live webinar video to receive CME credit.

Available Credit

  • 1.00 ABIM Medical Knowledge
  • 1.00 AMA PRA Category 1 Credit™
Please login or register to take this course.